Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. My name is Chloe and I will be your conference operator today. At this time, I would like to welcome everyone to the KWO Forum of Therapeutics First Quarter 2025 Financial Results Conference Call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would like to turn the call over to Brendan Strong, Senior Vice President, Investor Relations and Corporate Communications. Thank you. Please go ahead. Thank you, Chloe, and thank you all for joining us on today's conference call to discuss CarioFarm's first quarter 2025 financial results and recent company progress. We issued a press release after the market closed, detailing our financial results for the first quarter of 2025. This release, along with a slide presentation that we will reference during today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Reshma, Sohania, and Lori, who will provide an update on our results for the first quarter of 2025 and review new data that we are sharing for the first time today in myelofibrosis. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on slide three. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor section of our most recent Form 10-Q and 10-K on file with the SEC and in other filings that we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may e...